As a new company I am averaging in with their promising drugs..Double bottom in place.........
Aileron Therapeutics ($ALRN)
Therapy: ALRN-6924
Disease: T- and NK-cell lymphomas
News: ALRN has published preclinical findings for their stapled peptide ALRN-6924 in patient-derived xenograft models of T- and natural killer (NK)-cell lymphomas. The findings were published in Nature Communications. The activity of ALRN-6924 was shown to be favorable compared with standard romidepsin across a number of subforms of these tumors, and the paper also mentions that the researchers have observed a complete remission in a patient with angioimmunoblastic T-cell lymphoma, providing a rationale for ongoing development.
Looking forward: The preclinical work demonstrates that the interface between Mdm2 and p53 is an actionable target in preclinical models of lymphoma, which is a pretty marvelous feat in my book. We've known for a very long time that p53 is a promising target, since it is a potent tumor suppressor when active. Mdm2 inhibits p53 activity in vivo, which can help to drive tumor growth. The observation of a complete remission in a patient is definitely favorable, as well, and support the ongoing work in this space.
Cash Position and Guidance: Cash, cash equivalents and investments as of
March 31, 2018 were $43.3 million, compared to $50.8 million as of
December 31, 2017. The Company believes that its cash, cash equivalents
and investments as of March 31, 2018 will enable the Company to fund its
operating expenses and capital expenditure requirements into the second
half of 2019.
